ArticleJACC. Case reports2025
Avoiding Pacemaker Implantation by Using Intracardiac Echocardiography During Self-Expanding Valve TAVR.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracardiac echocardiography during transcatheter aortic valve replacement (TAVR) clarifies the relationship between the bioprosthetic valve and membranous septum (MS), reducing atrioventricular conduction disturbances. CASE SUMMARY: An 82-year-old man with severe aortic stenosis underwent transfemoral TAVR owing to annular calcification; we used a self-expanding 29-mm Evolut FX valve (Medtronic) for the procedure. Computed tomography showed a short MS length, indicating high risk for conduction disturbance. Intracardiac echocardiography revealed that although the valve extended beyond the MS, calcifications at the noncoronary cusp (NCC) and right coronary cusp (RCC) would prevent contact with the muscular septum, avoiding the need for permanent pacemaker implantation (PPI). DISCUSSION: The conduction pathway and the MS are located between the NCC and RCC. Severe calcification at these sites may reduce the risk of PPI. TAKE-HOME MESSAGE: Significant valve calcification at the NCC and RCC may allow deep implantation during TAVR without PPI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.